Overview

FOLFIRINOX + 9-Ing-41 + Losartan In Adenocarcinoma

Status:
Not yet recruiting
Trial end date:
2024-07-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to find out if an experimental drug will prevent metastatic pancreatic adenocarcinoma from becoming resistant to standard treatment for the disease. The names of the study drugs involved in this study are: - 9-ING-41 - Losartan - Ferumoxytol - FOLFIRINOX (made up of 4 different drugs): - 5-Fluorouracil (5-FU) - Oxaliplatin - Irinotecan - Leucovorin
Phase:
Phase 2
Details
Lead Sponsor:
Colin D. Weekes, M.D.
Collaborators:
Actuate Therapeutics
Lustgarten Foundation
Treatments:
Losartan